Kiromic Biopharma, Inc.
KRBPDelisted Nov 20, 2023- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001792581
Kiromic Biopharma, Inc. was delisted on Nov 20, 2023; its insiders filed their last Form 4 on Aug 26, 2024; no institution reported holding it in 13F filings for Q3 2023; no superinvestor held it.
13F holders, Q1 2023
Institutional positions in Kiromic Biopharma, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 7
- −4 vs. Q4 2022
- Shares held
- 20.1K
- −678.5K (−97.1%) vs. Q4 2022
- Total value
- $78.2K
- −$48.0K (−38.0%) vs. Q4 2022
- New holders
- 2
- 0 more added
- Sold out
- 6
- 5 more reduced
1 institution that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KRBP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 1 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 5 | $6.13K |
| Q1 2023 | 7 | $78.2K |
| Q4 2022 | 12 | $145.5K |
| Q3 2022 | 16 | $90.3K |
| Q2 2022 | 17 | $200.0K |
| Q1 2022 | 20 | $1.73M |
| Q4 2021 | 21 | $3.82M |
| Q3 2021 | 23 | $7.49M |
| Q2 2021 | 16 | $11.9M |
| Q1 2021 | 13 | $3.34M |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Kiromic Biopharma, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Susquehanna International Group, LLP | 16,457 | $64.2K | 0.00% | +16,457 | New |
| Tower Research Capital LLC (TRC) | 1,559 | $6.00K | 0.00% | −3,116−66.7% | Reduced |
| UBS Group AG | 1,222 | $4.72K | 0.00% | −37,535−96.8% | Reduced |
| BlackRock Inc. | 809 | $3.12K | 0.00% | +809 | New |
| Morgan Stanley | 40 | $154 | 0.00% | −1,166−96.7% | Reduced |
| Group One Trading, L.P. | 8 | $31 | 0.00% | −184−95.8% | Reduced |
| Wells Fargo & Company | 4 | $15 | 0.00% | −73−94.8% | Reduced |
| Sabby Management, LLC | 0 | $0 | 0.00% | −549,944−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −40,962−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −31,810−100.0% | Sold out |
| State Street Corp | 0 | $0 | 0.00% | −16,976−100.0% | Sold out |
| WealthTrust Axiom LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| The PNC Financial Services Group, Inc. | 0 | $0 | 0.00% | −4,000−100.0% | Sold out |
| Zeke Capital Advisors, LLC | – | – | – | – | Not filed |